Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00935246

Enrollment

202

Registered

2009-07-08

Start date

2008-12-31

Completion date

2016-12-31

Last updated

2015-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Reaction to Drug, Continuous Antidepressant Abuse, Depression

Keywords

Genomic devices, Prediction of Escitalopram Response, Depressed Patients

Brief summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Detailed description

The purposes of this study are: 1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning) 2. To improve the success rate of escitalopram treatment response for depressed patients

Interventions

DRUGEscitalopram

Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 89 Years

Healthy volunteers

Inclusion criteria

1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition. 2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion criteria

1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Design outcomes

Primary

Measure	Time frame
antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks	8 weeks

Secondary

Measure	Time frame
biological value at 0 week and 8 weeks	8 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026